Abstract
Vascular manifestations are rare and cause morbidity and mortality in patients with Behçet’s disease (BD). Owing to the lack of evidence, we aimed to retrospectively evaluate the clinical features and associated risk factors of vascular BD. This retrospective cohort study was conducted at the Rheumatology Research Center, Tehran, Iran, from 1982 to 2018. The demographics, laboratory results, severity at diagnosis, diagnosis interval, and clinical manifestations divided into major events as well as sub-events at each visit were recorded. Of 57 patients, 43 (75.44%) were male, with an M:F ratio of 3.07. The mean age at onset was 32.00 ± 8.05 years. The three major clinical events repeated during the study period were mucocutaneous (41.30%), ocular (17%), and vascular (16.8%). DVT (33.3 %), SVT (21.84 %), and thrombosis of the large vein extremities (17.24 %) were the most common vascular events. The presence of HLA-B51 was found to have a statistically significant impact on the distinct number of events (B=-0.39, 95% CI: -0.74, -0.03, p=0.039). Severity at diagnosis (Moderate Vs. mild and Severe Vs. mild) were found to be statistically significant predictors of the logarithm of distinct number of events (B=-0.68, 95% CI: -1.13, -0.24, p=0.004; B=-0.51, 95% CI: -0.93, -0.10, p=0.020). The odds of developing vasculitis decreased faster in patients with a family history of OA than in those without a family history of OA. The other variables were not found to have a statistically significant impact on the logarithm of distinct number of events. A family history of OA, HLA- B51 positivity, and disease severity at diagnosis were associated with the occurrence of vascular BD. Further longitudinal and large-sample size studies should be conducted to evaluate the risk factors for vascular events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved under the supervision of Qom University of Medical Sciences” Research and Ethics (IR.MUQ.REC.1402.216), and conducted according to the Helsinki ethics criteria.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
